Fund Gurus

Endologix: Strong Growth Prospects Present Upside

Medical devices and technology companies continue their strong performance of late as investors look ahead to the future of healthcare. We have recently talked about a number of compelling investments in this space, such as Immunogen (NASDAQ:IMGN) and Steris Corp (NYSE:STE). The following article continues the trend and looks at the fast growing company Endologix (NASDAQ:ELGX) with an advanced patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). With over 200,000 people diagnosed in the US each year, ELGX continues to gain market share and has impressive upside capabilities over the medium term offering over 40% upside at current levels.

The Disease

While 200,000 people are diagnosed each year in the US, it...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
PRO Top long ideas returned 21.7% in 2016**
"As a PRO member, we get uniquely valuable perspective that go beyond our quantiative analysis... We rely on PRO to get beyond the numbers quickly and add much needed perspective. It keeps me ahead of the next big thing. - Mark Choate, Malaga Cove Capital"
Mark Choate, Malaga Cove Capital
"Contributors (writers and commentators), often have a long history in the secuirities they opine on and some are clearly well positioned industry participants with detailed industry views that can help provide color on where the skeletons are buried in a particular secuirity and/or industry."
Jim Roumell, Roumell Asset Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details